Physician profile
Niraj Niraula
NPI 1215223722
$12,357.67
in general payments reported to CMS, 2019-2025
31 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,111 · 2020: $546 · 2021: $953 · 2022: $442 · 2023: $6,809 · 2024: $1,064 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,226 · Food and Beverage: $3,982 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,225.56 |
| Food and Beverage | $3,982.45 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noah Medical Corporation | $3,231.06 | 2023-2025 | Galaxy |
| Pulmonx Corporation | $2,710.51 | 2023-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Intuitive Surgical, INC. | $1,694.38 | 2023 | Da Vinci Surgical System |
| United Therapeutics Corporation | $1,487.28 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Actelion Pharmaceuticals US, INC. | $952.77 | 2019-2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $623.31 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $213.35 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $152.54 | 2019-2024 | Winrevair |
| Jazz Pharmaceuticals INC. | $147.09 | 2019-2022 | |
| Insmed, INC. | $116.58 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $115.34 | 2021-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.44 | 2019-2021 | |
| Baxter Healthcare | $113.93 | 2025 | |
| Mallinckrodt Hospital Products INC. | $81.43 | 2020-2022 | |
| Portola Pharmaceuticals, LLC | $81.39 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $77.39 | 2019 | |
| Genentech USA, INC. | $54.32 | 2019-2021 | |
| Amgen INC. | $53.39 | 2022 | |
| Harmony Biosciences LLC | $41.24 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $36.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.22 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $34.30 | 2021 | |
| Genzyme Corporation | $33.04 | 2019-2021 | |
| Mylan Specialty L.P. | $32.49 | 2019 | |
| Sunovion Pharmaceuticals INC. | $31.06 | 2019 | |
| Electromed, INC. | $18.64 | 2021 | |
| Abbott Laboratories | $18.24 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.30 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.54 | 2021 | |
| Pfizer INC. | $13.61 | 2019 | |
| Eisai INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Niraula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.